Who We Serve

Brokers, Wealth Managers, Financial Planners, RIAs, Insitutional investors, Academic institutions, Governmental institutions, Financial Marketers, Corporate and Professional Services, and individual investors all benefit from our proprietary Bio-Intelligence Reports.

In 2021 Cowen Research’s biotech team published a report concluding investors would have better luck ignoring—or even doing the complete opposite—of what biotech equity analysts advise.Meanwhile, the world saw the largest class of Biotech IPOs to date (81). The IPOs raised $12.2 Billion. Today, over 60% trade below their IPO price, while the top of their class boast up to a 156% increase, which the "trained expert analysts" missed.